ERASErasca, Inc.

Filing: 8-K (Items 2.02, 9.01) | Filed with the SEC on: November 12, 2026 Current Price: $14.58 | Today's Change: -7.59%

---

What Happened

Erasca, Inc. filed an 8-K with the SEC on November 12, 2026, disclosing its Q3 FY2026 financial results. The company reported a net loss of $30,966,000 and an operating loss of $108,301,000 for the quarter. Basic and diluted earnings per share both came in at -$0.34, reflecting the continued cash consumption characteristic of a clinical-stage biopharmaceutical company investing heavily in its RAS/MAPK pathway pipeline.

Why It Matters

The headline figures present a nuanced picture for investors:

• The net loss of ~$31M is notably narrower than the operating loss of ~$108M, a gap that likely reflects significant non-cash or non-operating items — the magnitude of this divergence warrants close examination of the full financial statements.
• An operating loss of $108.3M in a single quarter signals that Erasca continues to burn cash at a substantial rate, which raises ongoing questions about runway and potential future dilution.
• The stock's -7.59% decline today suggests the market is reacting negatively to the results, though without revenue figures provided in the structured filing data, it is not possible to contextualize the losses against any top-line performance from this filing alone.
• For investors who have followed our existing coverage since initiation in September 2026, this quarterly update is an important data point in tracking how efficiently Erasca is deploying capital against its clinical milestones.

Analysis

The wide gap between the operating loss ($108.3M) and the net loss ($31.0M) is the most striking feature of this disclosure. A difference of roughly $77M between the two figures points to material non-operating income — potentially from interest income on its cash reserves, fair value changes in financial instruments, or other balance sheet items — none of which are captured in the structured XBRL data provided. Investors should scrutinize the full income statement and cash flow statement when the complete filing becomes available to understand the true economic picture.

The EPS figure of -$0.34 per share, while meaningful, is secondary to the cash burn trajectory for a pre-revenue or early-revenue oncology company like Erasca. What to watch next:

• Pipeline readouts: Any clinical updates tied to its RAS/MAPK inhibitor programs that could justify the ongoing investment.
• Cash and equivalents balance: The most critical number for assessing near-term operational continuity given the operating loss rate.
• Non-operating income composition: Understanding what is bridging the gap between operating and net loss is essential to assessing the sustainability of the current burn profile.

The sharp intraday decline underscores that the market is recalibrating its near-term expectations for ERAS following this disclosure.

---

Disclaimer

This report is a news and informational analysis based solely on data from Erasca's SEC filing and is not investment advice. No rating or price target is issued in this report. Readers should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions. Past financial results are not indicative of future performance.

Existing Coverage

StockWatch has full coverage on ERAS, published 2026-09-18. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-12. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1761918/000119312526458350/eras-20261112.htm